SPOTLIGHT: Baxter bullish on Gammagard
Baxter International says that a preliminary analysis of data from a Phase II study of Gammagard for Alzheimer's has produced enough encouraging signs to lay the groundwork for Phase III. The next study should get underway in early 2008. Release
Be the first to comment
Comments
Post new comment
Paid Research Reports
- RNA therapy: the next big thing after monoclonal antibodies?
- Biotech M&A Strategies: Deal assessments, trends and future prospects
- The Dermatology Market Outlook to 2013: Competitive landscape, pipeline analysis and growth opportunities
- Pipeline Insight: Cancer Overview - Breast, Gynecological, Genitourinary - Diverse drugs approaching the market for many tumor t
- Sales Force Effectiveness
- Forecast Model: Antidyslipidemics - Genericization and negative trial data drive market shrinkage
